Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab.
Fischer S, Cohnen S, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, Zundler S, Rath T, Krebs S, Dörje F, Uter W, Nagore D, Meyer S, Neurath MF, Atreya R.
Fischer S, et al. Among authors: krebs s.
Therap Adv Gastroenterol. 2021 Jan 14;14:1756284820982802. doi: 10.1177/1756284820982802. eCollection 2021.
Therap Adv Gastroenterol. 2021.
PMID: 33505519
Free PMC article.